Solu-Cortef Stungulyfsstofn og leysir, lausn 250 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-cortef stungulyfsstofn og leysir, lausn 250 mg

pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 250 mg

Tibolon Orifarm Tafla 2,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

tibolon orifarm tafla 2,5 mg

orifarm generics a/s - tibolonum inn - tafla - 2,5 mg

Vivelle dot Forðaplástur 100 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 100 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 100 míkróg

Vivelle dot Forðaplástur 25 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 25 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 25 míkróg

Vivelle dot Forðaplástur 37,5 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 37,5 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 37,5 míkróg

Vivelle dot Forðaplástur 50 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 50 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 50 míkróg

Vivelle dot Forðaplástur 75 míkróg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vivelle dot forðaplástur 75 míkróg

sandoz a/s - estradiolum inn - forðaplástur - 75 míkróg

Tibsovo Evrópusambandið - íslenska - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Solu-Medrol Stungulyfsstofn og leysir, lausn 125 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 125 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 125 mg

Solu-Medrol Stungulyfsstofn og leysir, lausn 500 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 500 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 500 mg